Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06597383 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

The RApid Switch From 1st Generation Somatostatin Analogues to PaSireOtiDe In Acromegaly

Study acronym: RAPSODIA
StatusUnknown
PhaseNot specified
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated September 19, 2024 (before its estimated November 2024 completion). Its status may not reflect the trial's current state.

Record History

  1. Changed Registry marked status Unknown (sponsor has not verified the record since Sep 2024); last known: Recruiting
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is an observational, retrospective, national multicenter study aimed to evaluate the impact and efficacy of Time To Switch (TTS) from first-line to second-line medical therapy in Acromegaly.
Trial Details
NCT Number NCT06597383
Lead Sponsor IRCCS San Raffaele
Collaborators: University of Turin, Italy, University of Padova, Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Conditions Acromegaly
Enrollment 100 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov